Anusiyanthan Isaac Mariampillai1, Josephine Pineda Dela Cruz1, Jason Suh2, Abirami Sivapiragasam3, Kyle Nevins4, Alexander A Hindenburg5. 1. Department of Hematology and Oncology, NYU Winthrop Hospital, Mineola, NY, U.S.A. 2. Department of Hematology and Oncology, Valley-Mount Sinai Comprehensive Cancer Care, Paramus, NJ, U.S.A. 3. Department of Medicine, SUNY Upstate University Hospital, Syracuse, NY, U.S.A. 4. Northwell Health Laboratories, New York, NY, U.S.A. 5. Department of Hematology and Oncology, NYU Winthrop Hospital, Mineola, NY, U.S.A. ahindenburg@nyuwinthrop.org.
Abstract
BACKGROUND: Cancer antigen CA72-4 is a tumor marker found to be elevated in a variety of human adenocarcinomas. Using the DRG TM-CA72-4, we quantified the elevation of CA72-4 compared to current United States Food And Drug Administration-approved tumor markers in various cancer types. MATERIALS AND METHODS: We conducted a prospective, single-center study enrolling 96 patients between March 2013 and August 2016 with different locally advanced, unresectable or metastatic cancer known to express CA72-4. Quantification of CA72-4 was performed according to the manufacturer's instructions using the DRG TM-CA72-4 enzyme-linked immunosorbent assay kit and the positivity rates were calculated. RESULTS: CA72-4 expression varied with tumoral site of origin, with the highest positivity rates found in pancreatic and ovarian malignancies. Correlation with clinical activity was also noted in some patients. CONCLUSION: CA72-4 may have a potential role as an adjunct to conventional biomarkers in disease monitoring of pancreatic, ovarian and colorectal carcinomas. Copyright
BACKGROUND:Cancer antigen CA72-4 is a tumor marker found to be elevated in a variety of humanadenocarcinomas. Using the DRG TM-CA72-4, we quantified the elevation of CA72-4 compared to current United States Food And Drug Administration-approved tumor markers in various cancer types. MATERIALS AND METHODS: We conducted a prospective, single-center study enrolling 96 patients between March 2013 and August 2016 with different locally advanced, unresectable or metastatic cancer known to express CA72-4. Quantification of CA72-4 was performed according to the manufacturer's instructions using the DRG TM-CA72-4 enzyme-linked immunosorbent assay kit and the positivity rates were calculated. RESULTS: CA72-4 expression varied with tumoral site of origin, with the highest positivity rates found in pancreatic and ovarian malignancies. Correlation with clinical activity was also noted in some patients. CONCLUSION: CA72-4 may have a potential role as an adjunct to conventional biomarkers in disease monitoring of pancreatic, ovarian and colorectal carcinomas. Copyright
Authors: Saw-Lin Oo; Shishir Venkatesh; Vaithinathan Karthikeyan; Clement Manohar Arava; Spoorthy Pathikonda; Peter K N Yu; Terrence C K Lau; Xianfeng Chen; Vellaisamy A L Roy Journal: Sensors (Basel) Date: 2021-04-09 Impact factor: 3.576